Tarsus Pharmaceuticals, Inc. (TARS) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 8 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for TARS is $89.00, representing a +20.6% upside from the current price of $73.81. Price targets range from a low of $68.00 to a high of $100.00.
